Clinical Value of an LDH–CA125–NLR Panel for Diagnosis, Platinum Resistance, and Prognostic Assessment in Epithelial Ovarian Cancer
Current Oncology · 2026
DOI: 10.3390/curroncol33090551 ↗Kurz gefasst
Fachartikel in der Zeitschrift Current Oncology, 2026. Verfasst von Shuiqing Xu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Beijing Chaoyang Hospital, Capital Medical University, 8 Gongti South Road, Chaoyang District, Beijing 10002…. Hauptthemen laut MEDLINE: CA-125 Antigen, L-Lactate Dehydrogenase, Carcinoma, Ovarian Epithelial, Ovarian Neoplasms. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
(1) Background/Objective: Routine blood tests may provide useful information at different stages of epithelial ovarian cancer (EOC) management. This study evaluated continuous lactate dehydrogenase (LDH), carbohydrate antigen 125 (CA125), and neutrophil-to-lymphocyte ratio (NLR) values for diagnostic discrimination in epithelial ovarian cancer (EOC) and, separately, triple-positive status in relation to platinum resistance and survival. (2)
Methods
This retrospective study included 238 patients with EOC and 238 individually matched patients with benign ovarian lesions. Continuous biomarkers were entered into logistic regression models for diagnosis. Triple-positive status was defined as LDH > 195.5 U/L, CA125 > 35.37 U/mL, and NLR > 2.63. Logistic regression was used for platinum resistance and Cox regression for progression-free survival (PFS) and overall survival (OS). Bootstrap internal validation was performed for the diagnostic models and PFS nomogram. (3)
Results
The continuous LDH + CA125 + NLR model yielded an AUC of 0.873, with 75.97% sensitivity and 88.66% specificity; AUCs were 0.751 in early-stage and 0.958 in advanced-stage EOC. Adding NLR to LDH + CA125 did not significantly improve the AUC overall or within stage groups. Triple-positive status was associated with platinum resistance (adjusted OR = 3.488, 95% CI 1.504–8.087; p = 0.004), shorter PFS (adjusted HR = 3.109, 95% CI 1.772–5.456; p < 0.001), and shorter OS in advanced-stage EOC (adjusted HR = 3.538, 95% CI 1.385–9.038; p = 0.008). The PFS nomogram had a bootstrap-corrected C-index of 0.7521. (4)
Conclusions
The continuous three-marker model showed diagnostic discrimination in this selected surgical cohort, while triple-positive status was associated with platinum resistance and adverse survival outcomes. External validation is needed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, Beijing Chaoyang Hospital, Capital Medical University, 8 Gongti South Road, Chaoyang District, Beijing 100020, China.
- Chinese Institutes for Medical Research, Capital Medical University, Beijing 100069, China.
ORCID-Profile: Hua Li
Zitieren
APA
Xu, S., Guo, J., Zhao, Z., Zhai, Y., Liu, Y., & Li, H. (2026). Clinical Value of an LDH–CA125–NLR Panel for Diagnosis, Platinum Resistance, and Prognostic Assessment in Epithelial Ovarian Cancer. Current Oncology. https://doi.org/10.3390/curroncol33090551
Vancouver
Xu S, Guo J, Zhao Z, Zhai Y, Liu Y, Li H. Clinical Value of an LDH–CA125–NLR Panel for Diagnosis, Platinum Resistance, and Prognostic Assessment in Epithelial Ovarian Cancer. Current Oncology. 2026. doi:10.3390/curroncol33090551
BibTeX
@article{Xu2026,
author = {Xu, Shuiqing and Guo, Jinzhen and Zhao, Ziyi and Zhai, Yan and Liu, Yingying and Li, Hua},
title = {Clinical Value of an LDH–CA125–NLR Panel for Diagnosis, Platinum Resistance, and Prognostic Assessment in Epithelial Ovarian Cancer},
journal = {Current Oncology},
year = {2026},
doi = {10.3390/curroncol33090551}
}
EUVIMED